Physician profile
James Conner
NPI 1972766970
$1,493.48
in general payments reported to CMS, 2019-2025
23 companies · $423 in 2025
The $423 reported for 2025 was more than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $257 · 2020: $307 · 2021: $142 · 2022: $109 · 2023: $123 · 2024: $131 · 2025: $423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $678.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $677.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $613.64 | 2019-2023 | Da Vinci Surgical System |
| Braintree Laboratories, INC. | $127.02 | 2019-2025 | Sutab, Suflave |
| Exact Sciences Corporation | $126.36 | 2025 | The Cologuard Plus Collection Kit |
| Ethicon US, LLC | $109.06 | 2019-2025 | Enseal, Echelon Circular |
| Abbvie INC. | $85.15 | 2025 | |
| Medtronic, INC. | $46.84 | 2024-2025 | Altaviva, Interstim |
| Merck Sharp & Dohme LLC | $45.27 | 2024 | Dificid, Zerbaxa, Recarbrio |
| Kerecis Limited | $43.19 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Tela Bio, INC. | $31.60 | 2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Ferring Pharmaceuticals INC. | $29.07 | 2019 | |
| Azurity Pharmaceuticals, INC. | $27.68 | 2025 | Suflave |
| Boston Scientific Corporation | $25.63 | 2025 | Axonics |
| Aroa Biosurgery Incorporated | $25.06 | 2025 | |
| Axonics, INC. | $20.22 | 2024 | Axonics |
| Acera Surgical, INC. | $19.49 | 2025 | Restrata Wound Matrix |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acelrx Pharmaceuticals, INC. | $19.16 | 2021 | |
| Ardelyx, INC. | $17.39 | 2023 | Ibsrela |
| Baudax Bio INC. | $16.96 | 2021 | |
| Reprise Biomedical, INC. | $16.68 | 2025 | Miro3d |
| Takeda Pharmaceuticals U.S.A., INC. | $15.53 | 2021 | |
| Davol INC. | $13.99 | 2025 | Arista |
| Coloplast Corp | $12.66 | 2020 | |
| Mayne Pharma Commercial LLC | $5.83 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Conner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.